Canadian Cancer Trials Group Bulletins

Trial Management Group

IND.219 trial closed to accrual

IND.219, A Randomized Phase II Trial of Selumetinib in Patients Receiving Standard Pemetrexed and Platinum-Based Chemotherapy for the Treatment of Advanced or Metastatic KRAS Wildtype or Unknown Non-squamous Non-Small Cell Lung Cancer, is closed to accrual after completion of the interim analysis.

Although the trial is closed accrual, treatment and follow up of patients still on study will continue according to the protocol.

Primary Objective: To determine the efficacy, as determined by objective response rate, of selumetinib (intermittent or continuous) in patients with NSCLC not known to have KRAS mutation receiving standard pemetrexed and cisplatin chemotherapy compared to chemotherapy alone.

Secondary Objectives:
  • To assess the tolerability of selumetinib in patients receiving pemetrexed and cisplatin,
  • to explore the progression free survival of patients receiving selumetinib with pemetrexed and cisplatin to those receiving pemetrexed and cisplatin or carboplatin alone and
  • to explore whether KRAS mutation, other common mutations, or tumour based molecular signatures are predictive of selumetinib effect.
For more information please contact the Study Coordinator Pamela Brown-Walker: pbrown-walker@ctg.queensu.ca